Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6294820 | 0.90 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL6294821 | 0.90 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL6137965 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL6137960 | 0.82 | ALDH1A1 (0.39) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL6290215 | 0.81 | ALDH1A1 (0.38) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL6138512 | 0.81 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL6138515 | 0.81 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL6138269 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL6290170 | 0.80 | ALDH1A1 (0.32) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL6290954 | 0.79 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | claimed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | claimed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | claimed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | claimed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | claimed |
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | CHRNB2 24/4885CHRNA4 2/4885CHRM2 20/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | CHRNB2 48/4885CHRNA4 31/4885CHRM2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.